INOVIO Aktie

>INOVIO Aktienkurs

1.2 EUR -1.6% (Tradegate)

Ask: 1.21 EUR / 4500 Stück

Bid: 1.15 EUR / 1500 Stück

Tagesumsatz: 14769 Stück

Realtime Kurs von 8 bis 22 Uhr!

INOVIO Aktie über LYNX handeln

Intraday

1 Jahr

>INOVIO Performance

1 Woche: -34,8%

1 Monat: -37,2%

3 Monate: -14,3%

6 Monate: -36,8%

1 Jahr: -84,3%

laufendes Jahr: -33,7%

>INOVIO Aktie

Name:

INOVIO PHARMACEUTICAL INC

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US45773H4092 / A400EJ

Symbol/ Ticker:

GBM (Frankfurt) / INO (NASDAQ)

Kürzel:

FRA:GBM, ETR:GBM, GBM:GR, NASDAQ:INO

Index:

Webseite:

https://inovio.com/

Marktkapitalisierung:

66.28 Mio. EUR

Umsatz:

0.25 Mio. EUR

EBITDA:

-90.58 Mio. EUR

Gewinn je Aktie:

-2.38 EUR

Schulden:

9.79 Mio. EUR

Liquide Mittel:

59.38 Mio. EUR

Umsatz-/ Gewinnwachstum:

- / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

228.03 / 1.49 / -

Gewinnm./ Eigenkapitalr.:

- / -132.44%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

INOVIO

Letzte Datenerhebung:

05.07.25

>INOVIO Eigentümer

Aktien: 36.67 Mio. St.

f.h. Aktien: 33.08 Mio. St.

Insider Eigner: 0.73%

Instit. Eigner: 37.33%

Leerverk. Aktien: 17.9%

>INOVIO Peer Group

ACHIEVE LIFE

CHAMPIONS ONCOLOGY

CORVUS PHARMA

ELEDON

HARVARD BIOSCIENCE

OVID THERAPEUTICS

PLANET 13

SAGIMET

SINOPHARM ADR

SONIDA

>INOVIO Chart & Kurs - NASDAQ

>INOVIO News

03.07.25 - 14:03	INOVIO announces pricing of $25M public offering (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.07.25 - 13:33	INOVIO Announces Pricing of $25 Million Public Offering (PR Newswire)
	PLYMOUTH MEETING, Pa., July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the......

03.07.25 - 04:54	INOVIO Pharma Announces Proposed Public Offering (AFX)
	WASHINGTON (dpa-AFX) - INOVIO Pharmaceuticals Inc. (INO) announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof......

02.07.25 - 22:27	Inovio Pharmaceuticals announces proposed public offering of common stock and warrants (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.07.25 - 22:18	INOVIO Announces Proposed Public Offering (PR Newswire)
	PLYMOUTH MEETING, Pa., July 2, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that......

14.05.25 - 01:09	Inovio outlines BLA submission timeline for INO-3107 and reports $68.4M cash position while advancing DNA medicine pipeline (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.25 - 01:00	Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
	Inovio (INO) delivered earnings and revenue surprises of 31.08% and 30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...

13.05.25 - 22:27	Earnings Snapshot: INOVIO says current cash pile enough to support ops till Q1 2026 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.25 - 22:12	Inovio Pharmaceuticals GAAP EPS of -$0.51 beats by $0.23 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.25 - 22:09	INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
	On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025 Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated......

30.04.25 - 14:09	INOVIO to Present at Upcoming Scientific and Investor Conferences (PR Newswire)
	PLYMOUTH MEETING, Pa., April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be......

29.04.25 - 14:09	INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025 (PR Newswire)
	PLYMOUTH MEETING, Pa., April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter......

21.04.25 - 15:00	Bet on These 5 Top-Ranked Stocks With Rising P/E (Zacks)
	Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Carvana, Context Therapeutics Inc, Inovio Pharmaceuticals, ChargePoint and MSA Safety Inc....

09.04.25 - 19:45	Inovio (INO) Upgraded to Buy: Here′s What You Should Know (Zacks)
	Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

09.04.25 - 14:06	INOVIO to Present at Upcoming Scientific Conferences (PR Newswire)
	PLYMOUTH MEETING, Pa., April 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will highlight key......

19.03.25 - 13:33	Inovio aims for INO-3107 regulatory submission by mid-2025 while addressing key manufacturing issues (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.03.25 - 03:24	Inovio Pharmaceuticals (INO) Q4 2024 Earnings Call Transcript (Fool)
	INO earnings call for the period ending December 31, 2024....

18.03.25 - 21:48	Inovio Pharmaceuticals Inc. Q4 Income Declines (AFX)
	WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals Inc. (INO) released a profit for fourth quarter that decreased from last yearThe company's bottom line came in at $19.4 million, or $0.65 per share. T......

18.03.25 - 21:09	INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights (PR Newswire)
	Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and......

17.03.25 - 22:42	Inovio Pharmaceuticals Q4 2024 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Männer sind wie Luft, zwar versaut, aber unentbehrlich. - Michelle Pfeiffer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram